Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:51 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00684996 · National Cancer Institute (NCI) · PHASE1/PHASE2 · terminated · last registry update 2014-05-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ITGB3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-04-28Also stopped (terminated): National Cancer Institute (NCI), Cilengitide (NCT01122888)
- 2015-03-26Also stopped (withdrawn): St. Louis University, Abciximab + Placebo (NCT01932554)
- 2015-02-27Also stopped (terminated): Hospital Avicenne, TIROFIBAN (NCT00445263)
- 2015-02-09Results posted on the registry: Hospital Avicenne, TIROFIBAN (NCT00445263)
- 2014-12-08Results posted on the registry: EMD Serono, Cilengitide (2-times weekly) + cilengitide (5-times weekly) (NCT00813943)
- 2014-11-04Results posted on the registry: EMD Serono, Cilengitide + Temozolomide (NCT00689221)
- 2014-09-30Results posted on the registry: Merck KGaA, Darmstadt, Germany, Cilengitide + Cilengitide (NCT00842712)
- 2014-07-08Phase 3 first posted: Boehringer Ingelheim, Full dose TNK-tPA + Half dose TNK-tPA (NCT02181985)
- 2014-04-30Results posted on the registry: Merck KGaA, Darmstadt, Germany, Cilengitide 2000 mg once weekly + Cilengitide 2000 mg twice weekly (NCT00705016)
- 2014-04-25Also stopped (terminated): SOS Attaque Cérébrale, alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip) (NCT02016547)
- 2014-02-20Results posted on the registry: National Cancer Institute (NCI), cilengitide (NCT00679354)
- 2014-02-04Also stopped (terminated): Merck KGaA, Darmstadt, Germany, Drug (including placebo) (NCT01558687)
- 2013-08-19Results posted on the registry: Centocor, Inc., Intetumumab + Dacarbazine (NCT00246012)
- 2013-07-08Results posted on the registry: Atrium Medical Corporation, Abciximab local infusion (NCT00976521)
- 2013-06-05Also stopped (terminated): National Cancer Institute (NCI), cilengitide (NCT00082875)
- 2013-06-03Also stopped (terminated): National Cancer Institute (NCI), cilengitide (NCT00006222)
- 2013-05-20Results posted on the registry: Centocor, Inc., Docetaxel + Prednisone (NCT00537381)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision